Femasys (FEMY) Net Income towards Common Stockholders (2020 - 2025)
Femasys (FEMY) posted Net Income towards Common Stockholders of -$4.6 million for Q2 2025, up 22.23% on a QoQ basis from -$5.9 million in Q1 2025, and up 2.11% year-over-year from -$4.5 million in Q2 2024.
Femasys (FEMY) Net Income towards Common Stockholders (2020 - 2025) Analysis & Trends
Femasys' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$4.6 million for Q2 2025.
- Quarterly Net Income towards Common Stockholders rose 2.11% year-over-year to -$4.6 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$4.6 million (up 78.28% YoY) and the FY2025 annual result came in at -$18.6 million, up 1.0% from the prior year.
- Net Income towards Common Stockholders was -$4.6 million for Q2 2025 at Femasys, up from -$5.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$1.1 million in Q2 2021 and bottomed at -$5.9 million in Q1 2025.
- A 5-year average of -$3.5 million and a median of -$3.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders increased 27.09% — and 2022, when it slumped 143.21%.
- Femasys' Net Income towards Common Stockholders stood at -$2.4 million in 2021, then fell by 22.38% to -$2.9 million in 2022, then tumbled by 52.39% to -$4.4 million in 2023, then fell by 16.17% to -$5.1 million in 2024, then rose by 10.5% to -$4.6 million in 2025.
- Business Quant data shows FEMY's Net Income towards Common Stockholders at -$4.6 million in Q2 2025, -$5.9 million in Q1 2025, and -$5.1 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 126.93 Bn | 121.71 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 44.94 Bn | 44.13 Bn | 2.15 Bn | -274.00 Mn |
| 3 | Alcon | 33.13 Bn | 31.47 Bn | 1.53 Bn | 22.13 Bn |
| 4 | Medline | 32.87 Bn | 30.63 Bn | 1.84 Bn | 239.00 Mn |
| 5 | Resmed | 29.48 Bn | 27.82 Bn | 890.98 Mn | 398.73 Mn |
| 6 | West Pharmaceutical Services | 23.28 Bn | 22.84 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 14.11 Bn | 13.55 Bn | 1.10 Bn | 13.00 Mn |
| 8 | Cooper Companies | 13.80 Bn | 13.66 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Align Technology | 12.06 Bn | 11.00 Bn | 736.59 Mn | 112.77 Mn |
| 10 | Femasys | 14.23 Mn | 8.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -4.59 Mn |
| Mar 31, 2025 | -5.90 Mn |
| Dec 31, 2024 | -5.12 Mn |
| Sep 30, 2024 | -5.41 Mn |
| Jun 30, 2024 | -4.68 Mn |
| Mar 31, 2024 | -3.60 Mn |
| Dec 31, 2023 | -4.41 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | -2.89 Mn |
| Mar 31, 2023 | -2.95 Mn |
| Dec 31, 2022 | -2.89 Mn |
| Sep 30, 2022 | -2.98 Mn |
| Jun 30, 2022 | -2.63 Mn |
| Mar 31, 2022 | -2.88 Mn |
| Dec 31, 2021 | -2.36 Mn |
| Sep 30, 2021 | -2.26 Mn |
| Jun 30, 2021 | -1.08 Mn |
| Mar 31, 2021 | -1.83 Mn |
| Dec 31, 2020 | -1.66 Mn |
| Sep 30, 2020 | -1.57 Mn |